Just days ago, the rules on peptides changed.
The FDA cleared twelve of them for independent scientific review¹ — a move that could rapidly expand mainstream access.
On April 15, 2026, U.S. Secretary of Health Robert F. Kennedy Jr. announced that the FDA would remove twelve peptides from restricted Category 2 status.
The list includes BPC-157, GHK-Cu,KPV, Thymosin beta-4 fragment, Epitalon, MOTS-c, DSIP, Dihexa Acetate, Ibutamoren Mesylate, Melanotan II, Semax, and Cathelicidin LL-37.
Kennedy had been telegraphing the plan for weeks, describing himself as a “big fan” of peptides and crediting them with helping him recover from injuries.3
Then on February 27, 2026, on Episode #2461 of The Joe Rogan Experience, he signaled his intention to open a clear pathway for the category:
“My hope is that they will get moved to a place where people have access from ethical suppliers.” — Secretary Kennedy, JRE #2461, February 27, 2026²
Pressure had been building from within the industry as well. The Alliance for Pharmacy Compounding, which represents compounding pharmacies across the United States, had already warned that demand was outpacing regulation:
“Compounding pharmacies are being hammered by patients and prescribers to prepare these peptide drugs, and legally, they can't do it. Not yet anyway.” — Scott Brunner,CEO, Alliance for Pharmacy Compounding⁴
That regulatory gap is now beginning to close.
As early as July 2026, these peptides will begin independent scientific review by the Pharmacy Compounding Advisory Committee (PCAC)¹.
For companies operating on the front end of this shift, the implications are immediate.
The Precision Peptide Company (CSE:BPC | OTCQB: PNGAF) is already there. Three of the twelve peptides under review, BPC-157, GHK-Cu, and KPV, are part of its active product lines.
The company’s needle-free delivery formats include topical and oral products, along with a patch in development that uses a unique bio-dissolving lattice technology.
A growing peptide market, a regulatory shift toward broader access, and non-invasive delivery methods tailored for mainstream adoption are now in place.
The Category That Dethroned Cancer Immunotherapy
In 2023, the best-selling drug class in pharma was cancer immunotherapy — with Keytruda and Opdivo generating US$38.9 billion in annual sales.
In 2024, GLP-1 peptides overtook them, according to Global Data analyst Kevin Marcaida⁵.
Retail investors know the GLP-1 storywell. Ozempic. Wegovy. Mounjaro. Zepbound.
All four are peptides.
By mid-2024, the entire top-selling drug list had transformed. Immunology and oncology biologics were displaced, and peptides moved into the top ranks.
Semaglutide, the GLP-1 behind Wegovy and Ozempic, turned Novo Nordisk from a mid-cap into the most valuable company in Europe by August 2023, briefly surpassing LVMH⁶.
Tirzepatide, the GLP-1 in Zepbound and Mounjaro, pushed Eli Lilly past US$1 trillion in market capitalization on November 21, 2025 — the first healthcare company in history to cross that threshold⁷.
In the third quarter of 2025 alone,tirzepatide generated US$10.11 billion, eclipsing Merck's Keytruda as the best-selling drug franchise on Earth⁸.
Despite those figures, the growth curve might still be early. Morgan Stanley projects the GLP-1 category alone will reach up to US$150 billion in annual sales within 10 years⁹. According to Grand View Research, the broader peptide therapeutics market is forecast to reach US$294.58 billion by 2033, growing at 8.73% CAGR.¹⁰
Accelerating Into the Mainstream
Consumer demand for peptide therapies has moved into mainstream channels. Search volume for BPC-157 hit an all-time high in June 2024, and combined TikTok and YouTube views for #BPC157 have surpassed 50 million, according to a 2025 systematic review in HSS Journal¹¹.
The New York Times¹², Bloomberg¹³, and CNN¹⁴ have all run major features on peptide wellness in the past nine months.
U.S. imports of Chinese peptides and hormones doubled year-over-year, from US$164 million in the first nine months of 2024 to US$328 million in the same period of 2025¹².
And Big Pharma has been voting with capital. Since 2022, the disclosed value of peptide-focused M&A, partnerships, and licensing deals across the major pharmaceutical companies has exceeded US$40 billion¹⁵.
The pharmaceutical industry has made up its mind. The capital has been committed. What changed on April 15, 2026 is the regulatory environment for a market segment Big Pharma doesn’t serve.
That’s where The Precision Peptide Company (CSE: BPC | OTCQB: PNGAF) is positioned.
Needle-Free Delivery Unlocks Widespread Adoption
Peptides became the biggest drug class in pharma – even with self-injection as the primary delivery method. But for many consumers, that requirement remains a barrier. The published data on how adults feel about needles is unambiguous:
- 63.2% of adults experience needle phobia, according to a 2022 international study of 2,098 adults published in PLOS ONE¹⁶.
- Between 11.5 and 66 million U.S. adults may suffer from the clinical condition, per the Journal of Primary Care & Community Health¹⁷.
- Patients prefer a daily oral medication over a weekly injectable by approximately 3 to 1 when efficacy is equivalent, per the peer-reviewed REVISE study¹⁸.
That is a key barrier to growth in the peptide market – one The Precision Peptide Company (CSE: BPC | OTCQB: PNGAF) has built its product portfolio to address.Through its subsidiary, Amino Innovations, Precision Peptide develops the following formulas in patent-pending oral and topical formats:
- BPC-157 (Recovery)
- GHK-Cu (Dermal)
- KPV (Anti-Inflammatory)
And in October 2025, the Company announced its next-generation peptide patch platform — an innovation that expects to redefine peptide delivery¹⁹.
The Amino Innovations Patch uses bio-dissolving lattice technology to deliver peptides through the skin’s surface layers.
No pain. No mixing. No needles.
Its proprietary design achieves one-to-one equivalence to traditional injectable dosing. Thereby eliminating the reconstitution, sterile handling, and dosing measurement that have made peptides a clinical specialty rather than an everyday wellness product¹⁹.
The patches are compact, TSA-friendly, and shelf-stable for up to six months — no refrigeration, no preparation, no pharmacy visit needed.
Every patch is developed in the United States, manufactured in a cGMP-certified facility, and subject to rigorous third-party testing for pharmaceutical-grade purity, stability, and consistency¹⁹.
The initial patch launch expects to include two formulations.
The “Wolverine Stack Patch” combines BPC-157 with Thymosin Beta-4 (TB-4) — two peptides that have become the
recovery stack of choice across professional sports, Silicon Valley biohacking culture, and the Joe Rogan audience .
20,21,24
The TA-1 Patch is formulated for
immune support.
Both now sit inside the twelve-peptide reclassification window¹⁹.
“These new formulations represent a significant step forward in our mission to make advanced peptide science accessible and effortless.These patches are designed to empower individuals to enhance recovery, cellular health, and overall vitality in a simple, convenient, and needle-free format.”— Justin Kirkland, CSO and Co-Founder, Amino Innovations¹⁹
The collaboration with the Universityof Alberta targets the exact technical variables that have kept peptides in a syringe: bioavailability, permeability, and stability.
The patent-pending delivery platform setsThe Precision Peptide Company (CSE: BPC | OTCQB: PNGAF) apart from every peptide company still shipping injectables.
The last peptide wave ran on injections.1 Needle-free delivery is what could take the next one mainstream.
The Voices Already in the Room
Unlike most emerging health categories, the peptide story has been unfolding in public, led by names retail investors clearly recognize.
“My doctor actually told me about peptides a long time ago…they accentuate healing. Athletes swear by them, particularly BPC-157. There's a lot of evidence that it accelerates healing from injuries.”— Joe Rogan, JRE#1580²⁰
“One of the clear effects of BPC-157 is to both encourage cellular turnover as well as cellular migration, so new cells and cells moving into a given area, as well as new blood supply through the promotion of this process we call angiogenesis.”— Dr. Andrew Huberman, Huberman Lab²¹
“There's over 80 peptides that are already approved by the FDA… for medical use.”— Dr. Mark Hyman,The Doctor’s Farmacy Ep. 914²²
“In just one month, I have shut down gut inflammation…completely healed golfer's elbow… and healed a torn upper hamstring with lightning speed.”— Ben Greenfield, bengreenfieldlife.com²³
“And then there were a number of peptides like BPC-157… that I was consuming to hedge my bets… I've used that as far back as 15 years ago.”— The Tim Ferriss Show #826, September 2025²⁴
None of the individuals quoted above are affiliated with, or have endorsed, The Precision Peptide Company. Their remarks are reproduced here as publicly reported commentary on the peptide category.
The audience they reach —collectively in the tens of millions of listeners, readers, and followers — is the same audience now looking for regulated, needle-free peptide products.
That is the demand the Wolverine Stack Patch was designed to meet.
Research Has Been Building for Decades
Peptides are among the most studied molecules in modern medicine. These short amino acid chains act as biological messengers — regulating inflammation, tissue repair, metabolism, immune function, and cellular signalling.
According to the THPdb database published in PLOS ONE, the FDA has approved hundreds of peptide and peptide-protein therapeutics to date²⁵.
Insulin. Semaglutide. Tirzepatide. Liraglutide. Teriparatide. Octreotide. Leuprolide. Desmopressin. Oxytocin. Bremelanotide. Tesamorelin.
All peptides. All approved. All already in the pharmaceutical mainstream.
The specific compounds now under PCAC review carry decades of independent research behind them:
- GHK-Cu was first characterised in a 1980 Nature paper by Loren Pickart as a copper-binding plasma tripeptide. Subsequent research has linked it to the modulation of more than 4,000 human genes, with research exploring its role in wound healing and dermatological health.²⁶
- BPC-157 has been studied continuously since 1991 by the research group of Dr. Predrag Sikiric at the University of Zagreb, with dozens of peer-reviewed publications on tissue healing and angiogenesis²⁷.
- MOTS-c was discovered by USC researchers and published in Cell Metabolism in 2015 as the first functional mitochondrial-encoded peptide beyond humanin²⁸. New research is focusing on potential applications in metabolic disorders, including type 2 diabetes and metabolic syndrome
- Epitalon research, pioneered by Dr. Vladimir Khavinson in St. Petersburg, was independently replicated in 2025 by researchers at Brunel University London²⁹. It’s now being studied for its potential effects on age-related cellular decline.
This is not a new frontier. It is the most-published, longest-studied “new” drug class in medicine.
The compounds The Precision Peptide Company (CSE: BPC | OTCQB: PNGAF) formulates today are the same compounds that have been under continuous peer-reviewed investigation for decades.
“We have the products, the needle-free delivery platform, the manufacturing, and the research partnerships. Secretary Kennedy’s announcement is the clarity the industry has been waiting for. We were ready before it arrived.”— Pratap Sandhu, CEO, The Precision Peptide Company (CSE: BPC | OTCQB: PNGAF)
5 Reasons to Add The Precision Peptide Company (CSE: BPC | OTCQB: PNGAF) to Your Watchlist
- The New Best-Selling Drug Class - Peptides overtook cancer immunotherapy as the top-selling segment in pharma in 2024, helping push EliLilly past a US$1 trillion in market cap. The broader peptide therapeutics market is forecast at US$294.58 billion by 2033.31
- Positioned Ahead of a Key Regulatory Shift - The Pharmacy Compounding Advisory Committee reviews the twelve reclassified peptides in July 2026. Three of them, BPC-157, GHK-Cu, and KPV, are formulated in Precision Peptide product lines today.
- Needle-Free Delivery a Key Differentiator - Current product lines include oral and topical formulations, offering non-injectable delivery formats already in active use.
- Next-Generation Patch Delivery in Development - The company is also developing a patch built on bio-dissolving lattice technology, designed to deliver peptides without injection.
- cGMP Certified Infrastructure - Products are manufactured in a U.S.-based cGMP-certified facility and third-party tested for pharmaceutical-grade quality, with ongoing formulation research conducted in collaboration with the University of Alberta.
A Potentially Rare Convergence
Regulatory clarity, scientific validation, consumer demand, and delivery readiness rarely arrive at the sametime. They are converging now — and The Precision Peptide Company (CSE: BPC| OTCQB: PNGAF) is at the center of this growing market.
Take Action
Get Updates
Regulatory milestones, product launches, investor news.
